GSK price forecast: will it hold GBX 1,770 amid bullish momentum and overbought signals?

Traders Union
All News
Financial News
GSK slips 0.48% to GBX 1,770.00

Highlights

GSK plc trades at GBX 1,770.00, maintaining a strong bullish trend above MA-20, MA-50, and MA-200 despite a 0.48% daily decline.
GSK reported net profit growth of 2–3% year-on-year for the September 2025 quarter to ₹255–257.5 crore, despite a 3% revenue drop from GST transitions, seasonality, and a manufacturing fire.
Short-term overbought signals and intraday fatigue suggest possible consolidation within GBX 1,737.50 to GBX 1,872.00, with over 80% chance of further price gains unless GBX 1,695–1,700 support fails.

Net profit growth achieved amid revenue decline and supply setbacks

GSK reported a net profit growth of approximately 2–3% year-on-year for the September 2025 quarter, achieving net profit in the ₹255–257.5 crore range despite revenue falling 3% due to GST transitions, seasonal disruptions, and supply challenges from a manufacturing site fire. The company expanded into oncology by launching Jemperli and Zejula, which were well received by healthcare professionals. GSK also continued to grow its vaccines business and executed a strategic buyback, raising treasury shares to 255,283,844.

Overbought warnings rise as bullish trend faces fatigue signals

Technical analysis indicates a strong bullish structure, with GSK trading well above its short, medium, and long-term moving averages. The closest dynamic support sits at the Ichimoku Kijun (GBX 1,695.75), while resistance is seen at the GBX 1,800 psychological level. Momentum indicators show positive MACD readings on daily and weekly charts, although ADX suggests slightly weakening trend strength. However, overbought signals from CCI and RSI on daily and weekly timeframes, as well as elevated BBP readings, suggest caution, while the Awesome Oscillator remains neutral. Intraday price action reflects mild pressure after the open and growing short-term fatigue.

High probability of gains as overbought risks point to range trade

Looking ahead, GSK is expected to consolidate within the GBX 1,737.50 to GBX 1,872.00 range over the next five trading days. The likelihood of additional price gains remains very high, above 80%, though short-term overbought conditions could spur some consolidation. A decisive move above GBX 1,800–1,850 would signal continuation of the uptrend, while failure to hold the GBX 1,695–1,700 support area may trigger a deeper pullback.

Anton Kharitonov, expert at Traders Union, sees GSK holding a technically strong position above major moving averages despite short-term consolidation risks. He notes that overbought conditions and waning trend strength could cap further upside in the near term, especially given recent supply and revenue disruptions. Until a decisive breakout above GBX 1,800 is confirmed, his outlook remains defensive and scenario-based. "Base case is rangebound action between GBX 1,737.50 and GBX 1,872.00 — if GBX 1,695 fails, expect a deeper correction."

Previously it was noted that ongoing buyback activity and investor accumulation were offset by R&D pipeline risks in a period of low volatility and cautious sentiment. Technical analysis showed persistent bullish signals, with oscillators highlighting both overbought momentum and the need for caution amid mixed indicator readings.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.